As the pathophysiology of DM involves an increase in type-1 IFN signaling, as a last resort, we decided to use anifrolumab, a IFNAR1-blocking antibody, as an off-label targeted approach which proved extremely helpful in controlling her disease activity. This evidence concerns the gene IFNAR1 and dermatomyositis.